coming back to life ?

Always a good sign.

Plant Health Care PLC
22 October 2007


TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which
voting rights are attached (ii):

PLANT HEALTH CARE plc

2. Reason for the notification (please state Yes/No): ( )

An acquisition or disposal of voting rights: (NO)

An acquisition or disposal of financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached: (NO)

An event changing the breakdown of voting rights: (NO)
Other (please specify): (YES - Issued Share Capital Adjustment)

3. Full name of person(s) subject to the notification obligation (iii):

Gartmore Investment Limited

4. Full name of shareholder(s) (if different from 3.) (iv):

See attached schedule

5. Date of the transaction (and date on which the threshold is crossed or
reached if different) (v):

28/09/2007

6. Date on which issuer notified:

01/10/2007

7. Threshold(s) that is/are crossed or reached:
9%

8. Notified details:

A: Voting rights attached to shares

Class/type of shares if Situation previous to the Triggering transaction (vi)
possible using the ISIN
CODE
Number of Number of
shares voting Rights
(viii)

GB00B01JC540 3,415,820 3,415,820

Resulting situation after the triggering transaction (vii)
Class/type of Number of Number of voting rights (ix) % of voting rights
shares if shares
possible using
the ISIN CODE
Direct (x) Indirect (xi) Direct Indirect
GB00B01JC540 3,983,820 3,983,820 9.470%

B: Financial Instruments

Resulting situation after the triggering transaction (xii)
Type of Expiration Exercise/ Number of voting rights that may % of
financial Date Conversion be acquired if the instrument is voting
instrument (xiii) Period/Date exercised/ converted. rights
(xiv)

Total (A+B)

Number of % of voting
voting rights rights

3,983,820 9.470%

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments
are effectively held, if applicable (xv):

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

All shares are held indirectly. All figures are based on the company's issued
share capital of 42,069,375 as provided by Exshare.

Nice up move today!

More good news, Plant Health Care is looking pretty solid (imo).


Plant Health Care PLC
12 December 2007


PLANT HEALTH CARE PLC

('Plant Health Care' or 'the Company')

Plant Health Care and Monsanto sign agreement for the development and
commercialization of Harpin Technology

Plant Health Care Inc, a wholly-owned subsidiary of Plant Health Care plc (AIM:
PHC), and Monsanto Company (NYSE: MON) have entered into an agreement to
evaluate, develop and commercialize applications of Plant Health Care's
Harpin-based technology.

Plant Health Care's Harpin seed technology is aimed at suppressing nematodes in
crop settings. Under the agreement, Plant Health Care will grant Monsanto
certain exclusive rights to applications of its Harpin technology. In return
Plant Health Care will receive an undisclosed upfront payment, plus a milestone
payment dependent upon the progress of the development of the technology over
the next twelve months.

Once evaluations are complete, the companies estimate that the products could be
available to farmers by the end of the decade. At the time of commercialization,
Plant Health Care will also receive a royalty payment based on the acreage for
which the Harpin technology is supplied. Additional terms of the agreement were
not disclosed at this time.

John Brady, CEO of Plant Health Care, noted: 'This agreement represents a
significant step forward in the development of our company and provides an ideal
first platform for the Harpin technology. This agreement with Monsanto validates
the confidence that our Board has in the Harpin technology which we only
acquired earlier this year.'

About Monsanto Company
Monsanto Company is a leading global provider of technology-based solutions and
agricultural products that improve farm productivity and food quality. For more
information, please visit the company's web site at
www.monsanto.com
.

About Plant Health Care plc
Plant Health Care plc ('PHC') is a leading provider of natural products for
plants and soil. Established in 1995 in Pittsburgh (Pennsylvania) in the United
States, PHC currently has approximately 70 employees and has operations in the
United States, Mexico, the United Kingdom, Spain, and the Netherlands. The
Company listed on the AIM market of the London Stock Exchange in July 2004.
Ticker symbol is PHC.

PHC's products are aimed at the landscape, agriculture and land reclamation
industries and are environmentally beneficial. Through the commercialization of
these products, PHC is capitalizing on current long-term trends toward natural
systems and biological products for plant care and soil and water management.
Further information is available at:
www.planthealthcare.com

Plant Health Care PLC
19 December 2007


TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which
voting rights are attached (ii):

PLANT HEALTH CARE plc

2. Reason for the notification (please state Yes/No): ( )

An acquisition or disposal of voting rights: (YES)

An acquisition or disposal of financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached: ( )

An event changing the breakdown of voting rights: ( )

Other (please specify): ()

3. Full name of person(s) subject to the notification obligation (iii):


Aviva plc & its subsidiaries


4. Full name of shareholder(s) (if different from 3.) (iv):

Registerd holder:

CUIM Nominee Limited 61,265*

* denotes direct interest

Delta Lloyd Luxembourg Water & Climate Fund 146,000

Kadoorie McAuley International Limited 12,400

Ohra Milieutechnologie Fonds NV 132,500

Triodos Value Pioneer Fund 137,500

Vidacos Nominees Limited 1,838,816



5. Date of the transaction (and date on which the threshold is crossed or
reached if different) (v):


12 December 2007


6. Date on which issuer notified:

14 December 2007



7. Threshold(s) that is/are crossed or reached:


Below 5% to 5% Change at Combined Interest level



8. Notified details:

A: Voting rights attached to shares

Class/type of shares if Situation previous to the Triggering transaction (vi)
possible using the ISIN
CODE
Number of Number of
shares voting Rights
(viii)


GB00B01JC540 Below 5% Below 5%


Resulting situation after the triggering transaction (vii)
Class/type of Number of Number of voting rights (ix) % of voting rights
shares if possible shares
using the ISIN
CODE

Direct Direct (x) Indirect (xi) Direct Indirect


GB00B01JC540 61,265 61,265 2,267,216 0.14% 5.13%



B: Financial Instruments


Resulting situation after the triggering transaction (xii)

Type of Expiration Exercise/ Number of voting rights that may % of
financial Date Conversion be acquired if the instrument is voting
instrument (xiii) Period/Date exercised/ converted. rights
(xiv)



Total (A+B)


Number of % of voting
voting rights rights


2,328,481 5.27%



9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments
are effectively held, if applicable (xv):

See Section 4

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

Figures are based on a total number of voting rights of 44,214,229.

14. Contact name:

(i) Andrew Wood FCIS, Company Secretary

(II) Tim Redfern, Evolution Securities Limited

(iii) Jeremy Carey, Tavistock Communications

15. Contact telephone number:

(i) +44 (0)20 8866 5702
(ii) +44 (0)20 7071 4300
(iii) +44 (0)20 7920 3150

Annex to Notification Of Major Interests In Shares (xvi)

A: Identity of the person or legal entity subject to the notification obligation

Full name (including legal form for legal entities):

Aviva plc

Contact address (registered office for legal entities):

St Helen's, 1 Undershaft, London EC3P 3DQ

Phone number:

01603 684420

Other useful information (at least legal representative for legal persons):

Neil Whittaker

B: Identity of the notifier, if applicable (xvii)

Full name:

Contact address:


Phone number:

Other useful information (e.g. functional relationship with the person or legal
entity subject to the notification obligation)

END


19 December 2007

Plant Health Care PLC
09 January 2008



EMBARGOED: 09.00, 9 January 2008

PLANT HEALTH CARE PLC
('Plant Health Care' or 'the Company')

Field Trials Update

- Strong commercial field trial results in Harpin based N-Hibit and ProAct -

Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soil, will announce today, at the Beltwide Cotton Conferences in
Nashville, Tennessee that results of replicated N-Hibit(R) and ProActTM field
trials in 2007 demonstrated yield improvements in cotton of between 6% and 12%
when used in combination with nematicides.

N-Hibit(R) and ProActTM are EPA registered, Harpin based products which have, in
field trials, consistently demonstrated their efficacy in improving crop yields
by reducing harmful cyst nematodes. Harpin proteins are produced by diseases
which are harmful to plants and, as a result, the application of a Harpin based
technology, such as N-Hibit(R) or ProActTM, causes the plant to behave as though
being attacked, even in the absence of disease pressure. Consequently, the plant
activates its natural self-defence and growth system, improving yield, root mass
and overall plant biomass.

Plant Health Care develops, manufacturers and markets a range of innovative
Harpin Protein-based products (Harp-N-Tek(R)). Harpin based proteins have
demonstrated a reduction in nematode populations by on average 50 percent, in
numerous replicated and commercial field testing work undertaken over several
years by leading university plant pathologists and nematologists, crop
consultants and cotton producers.

Commenting on the trials, John Brady, Chief Executive of Plant Health Care,
said:

'In the Company's interim results statement, the board highlighted its belief in
the substantial commercial potential for our Harpin technology and undertaking
trials is an important part of the development process. The agreement signed
with Monsanto in December 2007, was a significant step in developing this
exciting technology and the success of these trials further validates the
board's belief in its potential.'

'In demonstrating such strong yield improvements in these recent tests,
particularly in conjunction with other, already established and widely used
nematicides, the prospects for Harpin are further strengthened and the board
will continue to explore opportunities available to it in order to exploit fully
the potential of this exciting technology.'

-Ends-

A good company, and a good looking chart to match.
Next stop 3 perhaps?

Plant Health Care PLC
21 January 2008



For release: 21 January 2008

PLANT HEALTH CARE PLC
('Plant Health Care' or 'the Company')

Product Update

Advance towards commercialisation of Myconate(R) in cereal crops

Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soils, is pleased to report that, based on the very encouraging
results of its 2007 Myconate(R) test programs in cereals, it has reached
agreement, on a non-exclusive basis, with several large, multi-national
agrochemical/seed companies to move forward in 2008 with testing and potential
commercialisation of Myconate(R) in cereal grain crops such as wheat, barley,
sorghum and oats. The testing partners were selected because of their
geographical reach and significant market share in the cereal grain markets.

These arrangements are a result of the outcome from the first independent tests
of Plant Health Care's Myconate(R) programmes in wheat and barley in the USA.
Following the impressive results demonstrated in wheat in Mexico, reported on 27
June 2007, the latest results demonstrate the efficacy of Myconate(R) in both
winter and spring sown wheat and in spring sown barley. Plant Health Care now
has compelling evidence of yield improvement, when Myconate(R) is applied to
three important representatives of the small cereal grains: wheat, barley and
sorghum.

Winter wheat grain yields were increased across five locations by a range of
5.4% to 9.4% depending on application method, timing and quantity applied.
Spring sown wheat and barley yields were increased by 5.9% and 11.9%
respectively. The results also demonstrated that yield gain was attributable to
increases in both grain number and grain weight.

The forthcoming extensive evaluations will be carried out during 2008. The
Company believes that the test partners, being large global businesses operating
in the agrochemical and/or seed markets, each has the capabilities to conduct
trials, and ultimately commercialise Myconate(R) across cereal crops in Europe,
the Americas and Australia/Asia.

John Brady, Chief Executive of Plant Health Care commented on the results: 'We
are extremely excited to be working with these global companies to develop a
path to commercialisation for Myconate(R) in these very important crops. Due to
the more regional nature of cereal grains we have opted not to grant an
exclusive agreement as we have in the past but have elected to move forward with
several testing partners who have historically demonstrated strengths in each
market.'

'These recent cereal grain tests demonstrated the ability of Myconate(R) to be
effective in a range of climatic conditions and provided us with important data
points when determining the optimal dose rates and timing for application.'

For further information please contact:

Plant Heath Care plc Tavistock Communications
John Brady, Chief Executive Jeremy Carey / Matt Ridsdale
Tel: 020 7920 3150 (21-25 January) Tel: 020 7920 3150
Tel: 001 603 525 3702 (Thereafter)

Evolution Securities Limited
Tim Worlledge / Tim Redfern
Tel: 020 7071 4300

Myconate(R) background
Through the stimulation of endogenous mycorrhizal fungi, PHC's novel Myconate(R)
technology helps crops to develop larger effective rooting volume. Myconate(R)
works by enhancing the growth of beneficial micro-organisms called mycorrhizal
fungi which colonize the roots of crop plants. With more mycorrhizal fungi at
work, each plant can draw more nutrients and moisture out of the soil. More
nutrients make for healthier plants, and significantly greater overall yields.
Plant Health Care believes Myconate(R) could be the key to changing the face of
farming. The safety and ease of application of Myconate(R) means that management
practices need not be over-hauled. The procedure is a straightforward blending
process, either tank mixing the Myconate(R) with the fertilizer during planting,
or applying the Myconate(R) to the seed before planting.

Plant Health Care PLC
21 January 2008



For release: 21 January 2008

PLANT HEALTH CARE PLC
('Plant Health Care' or 'the Company')

Trading Update

Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soil, provides a post year end update for 2007, ahead of the
announcement of its Preliminary Results in late March/early April 2008.

The Company has also announced today that following the 2007 Myconate(R) trial
results, Bayer CropScience has confirmed that it will move forward with the
second year of Myconate(R) testing. Bayer CropScience will be making a milestone
payment to Plant Health Care for the continuation of the cooperation into the
second year.

In addition, the Company has announced today that following very encouraging
results of its 2007 Myconate(R) testing programme in cereal crops it is moving
forward, in 2008, with further testing and commercialisation activities for the
application of Myconate(R) on cereal grain crops with several large,
international agrichemical and/or seed companies.

Plant Health Care's turnover for the year ended 31 December 2007 is expected to
be $18.4 million, up 35% on the prior year. Following significant investment in
market development of Myconate(R) and Harpin, the operating loss for the period
is expected to be approximately $4.4 million. In addition, it is expected that
there will be non-operating charges of approximately $0.8 million of which
approximately $0.4 million relates to amortisation of the value of executive
share incentives awarded and is a non-cash item. As a result, the loss before
tax for the period is expected to be approximately $5.3 million. At 31 December
2007, the Company had cash and cash equivalents of approximately $10.8 million.

In terms of turnover, 5% relates to licensing and milestone payments from
partners. The marginally higher than expected operating loss in 2007 is largely
due to an important Harpin deal being delayed. The directors now anticipate that
this deal, with one of the world's leading agrichemical companies, will be
completed in the first half of 2008.

Commenting, John Brady, Chief Executive of Plant Health Care said: 'In January
2007 we signed our first development and commercialisation agreement for
Myconate(R) with Bayer CropScience and in December we secured our first
agreement for our EPA-registered Harpin technology with Monsanto. These two
agreements represent very significant progress for our Company.

'I am very pleased with the advance made during 2007 as our Company continues to
move forward in its efforts of establishing the necessary channels to extract
considerable value from our natural technologies.'

-Ends-

Plant Health Care PLC
21 January 2008



For release: 21 January 2008

PLANT HEALTH CARE PLC
('Plant Health Care' or 'the Company')

Bayer CropScience moves forward with second year of Myconate(R) tests


Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soil, announces that following the 2007 trial results, Bayer
CropScience has confirmed that it will move forward with the second year of
Myconate(R) testing. Bayer CropScience will be making a milestone payment to
Plant Health Care for the continuation of the cooperation into the second year.
Financial details were not disclosed.

Bayer CropScience, the global leader in seed treatment products, offers a broad
portfolio of high-quality products to combat pests and fungal diseases. Plant
Health Care's Myconate(R) technology is known to help crops to develop larger
root mass through the stimulation of naturally occurring mycorrhizal fungi,
which in turn often leads to improved yields and enhanced stress resistance.
Both companies are collaborating on the further development of Myconate(R) as a
seed treatment product in corn, soybean, cotton and sunflower on a worldwide
basis.

Commenting, John Brady, Chief Executive of Plant Health Care said: 'We are
excited that Bayer CropScience has elected to move forward with the development
and trial programme and we look forward to working with them to further develop
the commercial potential of Myconate(R).'

-Ends-

Plant Health Care PLC
18 February 2008


Embargoed for release: 08.00, 18 February 2008

ASA and PHC Renew N-Hibit(R) Partnership Programme

Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soil, announces that its 'N-Hibit(R) Partnership' program with The
American Soybean Association (ASA) has been enhanced with a 'Satisfaction
Guarantee' for the 2008 growing season. The new program provides ASA members and
other qualified growers with a risk-free means to evaluate N-Hibit Seed
Treatment as a tool to lower Soybean Cyst Nematode (SCN) pressure and improve
soybean plant health and yield.

'ASA views this program as an opportunity for its members to maximise soybean
yield and profitability, and reduce the threat of SCN damage,' said ASA
President John Hoffman, a soybean producer from Waterloo, Iowa.

'Year after year and all across the country, results with N-Hibit Seed Treatment
have been positive,' said Mike Cloutier, Plant Health Care Vice President of
U.S. Sales. 'We want growers to share our confidence, and the Satisfaction
Guarantee assures them of a full refund of the purchase price paid for N-Hibit
if they are not fully satisfied with its performance on treated acreage.'

ASA member Michael Gray, of Elizabeth City, N.C., was one of the growers who
participated in the ASA Partnership Program in 2007. He reported a yield gain of
4.6 bushels per acre on his Partnership acres.

'Mid-season examination of the N-Hibit-treated plants showed no visible signs of
damage from soybean cyst nematode or from root knot nematode,' said Gray.
Measurements showed increased plant stand, nodes per acre, plant height, nodes
per plant, and plant weight in both roots and forage. Of these, plant stand
counts at 8 percent more and nodes per acre (a strong indicator of yield) at 15
percent more were significantly higher than in the untreated acres.

'The yield monitor showed we harvested 50.8 bushels per acre at 13 percent
moisture from the treated beans and 46.15 bushels from the untreated,' Gray
said. 'If it hadn't turned off so dry the second half of the season, I believe
that yield difference would have been even greater. I'm trying N-Hibit on more
acres in 2008.'

'Replicated and commercial soybean field trials across Midwestern and Southern
states in 2006 and 2007 showed an average yield gain of 7.2 percent, or 2.9
bushels per acre, with N-Hibit Gold CST over the untreated control, said Dr. Ned
French, Plant Health Care Director of Field Biology and Development. 'These
research trials have shown N-Hibit increases root mass and total plant weight
and health. N-Hibit produces more nodes per plant and per acre, which is a key
to increased yield.

'In addition to those trials, university field research has shown that N-Hibit
reduces SCN eggs significantly. We believe N-Hibit can be a very economical and
helpful tool in reducing SCN egg counts and damage in soybeans. Earlier
university research has shown that N-Hibit reduces Root Knot Nematode and
Reniform Nematode eggs among roots by about 50 percent,' Dr. French said.

-Ends-

For further information please contact:

Plant Heath Care plc Tavistock Evolution Securities
Communications Limited
John Brady, Chief Jeremy Carey/Matt Tim Worlledge/ Tim
Executive Ridsdale Redfern
Tel: 001 603 525 3702 Tel: 020 7920 3150 Tel: 020 7071 4300

Plant Health Care PLC
21 February 2008


Embargoed for release: 07.00, 21 February 2008

Plant Health Care ('PHC')

Statement regarding a Monsanto announcement

Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soil, would like to draw investors' attention to an announcement
issued by Monsanto on 20 February 2008. The announcement refers to PHC in two
paragraphs (see below) and PHC confirms that the Monsanto release is entirely in
line with the PHC release dated 12 December.

The Monsanto announcement is set out in full below.

'NEW YORK, Feb. 20 Monsanto (NYSE: MON) Company's technologies have placed it in
a unique position to help farmers meet the changing supply-demand patterns of
global agriculture, Monsanto's Executive Vice President of Strategy and
Operations, Carl Casale, will tell investors tomorrow. Casale will deliver his
remarks as part of a presentation at the Morgan Stanley Basic Materials
Conference 2008 on Thursday in New York.

Casale's presentation will discuss how there has been a fundamental shift in the
agricultural landscape creating a new demand-driven agriculture market fueled by
three main factors. These factors include increased protein demand from rising
incomes, demand for grain from China and biofuels.

'The real demand pull comes from China,' Casale said. 'To meet the protein
demands of this growing population, China will look outside of its agricultural
sector, providing an enormous demand pull for grain over the next decade.'

'The solution to meeting these demands is yield,' Casale said. 'In a
demand-driven environment opportunity is defined by scarcity or innovation,' he
said. 'Monsanto's strategy is targeted on innovation -- discovering and
developing technology that is game changing.'

Casale believes the company's innovation focus sets it apart, both in the value
created for farmers and the company's strategic opportunity. 'We will grow
because of what we do, how we invest and what we deliver -- not because of what
the commodity cycles do,' he said.

Casale believes that the company's ability to provide technology to boost
per-acre productivity will be key to helping farmers meet the needs of a
demand-driven market. These potential technologies, like Roundup Ready 2 Yield
soybeans, SmartStax corn and nitrogen-utilization corn are being developed to
drive yields to meet these demands, he said.

Monsanto Establishes Global Seed Treatment Platform

As a technology company with strong cash generation, Monsanto has the
opportunity to invest in growth areas for agriculture, Casale said.

As part of his presentation, Casale will announce that Monsanto is establishing
a global seed treatment platform. The company has entered into separate
agreements with Becker Underwood and Plant Health Care Inc., as novel components
of the platform for delivering proprietary seed treatments for corn, soybeans
and cotton.

The global platform is a natural complement to the company's seed strategy and
yield-enhancing technology pioneered by Monsanto through biotechnology and
breeding, as well as its collaborative approach to new technologies, Casale
said.

'As we develop our seed-treatment platform, we're planning to stake a leading
position in an underserved, but emerging category and to enter into a variety of
licensing and supply agreements,' Casale said. 'Seed treatments are the next
step in yield protection and delivery, and represent a high-margin global
opportunity.'

The global seed treatment industry generates annual sales of greater than $1.5
billion, with almost $900 million in the crops key to Monsanto's business.
Currently, Monsanto treats more than 1 billion pounds of seed each year and sees
the potential to expand treatment to new crops and new geographies, Casale said.

'The realizable yield in seeds is so valuable to farmers that seed treatments
are the next logical complement to further protect yield created by advanced
breeding and biotech traits,' said Casale.

Monsanto plans to begin offering seed treatments as early as the 2009 season. In
2009, Monsanto plans to treat all Roundup Ready 2 Yield soybeans with a
proprietary treatment, aimed at incremental yield boost in soybeans. Similarly
in 2010, Monsanto plans to have a proprietary seed treatment for the launch of
its SmartStax corn product, and the company is also working to have a seed
treatment solution for its Deltapine cotton varieties by 2011.

The agreement between Monsanto and Becker Underwood is focused on evaluating a
biological seed treatment aimed at helping soybeans improve both their nitrogen
fixation ability and overall plant performance. Monsanto is also working with
Plant Health Care Inc. to develop and commercialize a novel seed-based solution
for nematodes, a plant parasite that can severely limit crop yields around the
world in crops such as corn, soybeans, cotton and vegetables.

Casale's presentation slides and simultaneous audio webcast of the presentation
may be accessed by visiting the company's web site at
http://www.monsanto.com/

investors . Following tomorrow's live broadcast set for 8 a.m. ET, a replay of
the webcast will be available for two weeks through this same link.

Monsanto Company is a leading global provider of technology-based solutions and
agricultural products that improve farm productivity and food quality.' For
information on Monsanto, see:
http://www.monsanto.com/
.

Cautionary Statements Regarding Forward-Looking Information:

Certain statements contained in this release are 'forward-looking statements,'
such as statements concerning the company's anticipated financial results,
current and future product performance, regulatory approvals, business and
financial plans and other non-historical facts. These statements are based on
current expectations and currently available information. However, since these
statements are based on factors that involve risks and uncertainties, the
company's actual performance and results may differ materially from those
described or implied by such forward-looking statements. Factors that could
cause or contribute to such differences include, among others: continued
competition in seeds, traits and agricultural chemicals; the company's exposure
to various contingencies, including those related to intellectual property
protection, regulatory compliance and the speed with which approvals are
received, and public acceptance of biotechnology products; the success of the
company's research and development activities; the outcomes of major lawsuits,
including proceedings related to Solutia Inc.; developments related to foreign
currencies and economies; successful operation of recent acquisitions;
fluctuations in commodity prices; compliance with regulations affecting our
manufacturing; the accuracy of the company's estimates related to distribution
inventory levels; the company's ability to fund its short-term financing needs
and to obtain payment for the products that it sells; the effect of weather
conditions, natural disasters and accidents on the agriculture business or the
company's facilities; and other risks and factors detailed in the company's most
recent periodic report to the SEC. Undue reliance should not be placed on these
forward-looking statements, which are current only as of the date of this
release. The company disclaims any current intention or obligation to update any
forward-looking statements or any of the factors that may affect actual results.

CONTACT: media, Lee Quarles, +1-314-694-2330, or investors, Scarlett Lee
Foster, +1-314-694-8148, both of Monsanto

Web site:
http://www.monsanto.com/


For further information please visit
www.planthealthcare.com
or contact:

Plant Heath Care plc Evolution Securities Tavistock
Limited Communications
John Brady, Chief Executive Tim Worlledge/Tim Jeremy Carey/Matt
Redfern Ridsdale
Tel: 001 603 525 3702 Tel: 020 7071 4300 Tel: 020 7920 3150

Plant Health Care PLC
31 March 2008


For immediate release 31 March 2008


PLANT HEATH CARE PLC

('Plant Heath Care' or 'the Company')

Results for the year ended 31 December 2007


Plant Heath Care, (AIM: PHC.L), a leading provider of natural products for
plants and soil, announces its results for the year ended 31 December 2007.


Financial highlights:


Turnover up 34% to $18.3 million (2006: $13.7 million)

Gross profit up 37% to $8.4 million (2006: $6.1 million)

Gross margin up from 44.7% to 45.6%
- due to upfront fee income from our partners and entry into the
higher margin Harpin business

Loss before exceptional costs, costs of share-based payments, interest
and taxation of $4.4 million (2006: loss $2.5 million)

Net loss of $5.4 million (2006: loss of $3.0 million)

Net cash at 31 December of $9.8 million (2006: $3.7 million)


Operational highlights:

First Myconate manufacture and supply agreement signed with Bayer
Cropscience in January 2007
- exclusive for seed-coated corn, soybean, cotton and sunflower

Agreement signed with Monsanto to evaluate, develop and commercialise
certain applications of the Harpin-based technology
- made possible by the acquisition of the Harpin intellectual
property from Eden Bioscience

Significant contribution from US agriculture division in its first full
year of operation

New share capital of $10 million raised in September

Post year end: Steve Weaver appointed to the Board of Directors as
Finance Director on 28 March 2008



Commenting on the results, Chief Executive John Brady said: 'Last year was
another important one for Plant Health Care. We signed our first two major
partnership deals with Bayer CropScience and Monsanto for Myconate and Harpin
respectively. These agreements have taken us further towards achieving our goal
of becoming the world's leading supplier of natural products for the promotion
of plant heath and growth.


'Plant Health Care's ability to fulfil the need for higher yields on existing
land has been validated by these partnership deals. With our stable of effective
natural technologies, we are extremely well positioned to offer further
solutions to help meet this global challenge, and as such, the macro environment
remains favourable.


'In 2007 we continued our pursuit of sales growth. Our performance was pleasing
with record revenue in almost all business units; in particular, in its first
full year of operation, our US agriculture division successfully introduced
Plant Health Care into what will be an important market for our future success.'


For further information:
Plant Heath Care plc

John Brady, Chief Executive

31 March - 4 April Tel: 020 7920 3150

Therafter: 001 603 525 3702


Evolution Securities Limited Tavistock Communications

Tim Worlledge/ Tim Redfern Jeremy Carey/Matt Ridsdale

Tel: 020 7071 4300 Tel: 020 7920 3150


Notes to editors

Plant Heath Care was established in 1995 in Pittsburgh (Pennsylvania) in the
United States. Its products are aimed at the agriculture, commercial landscaping
and land reclamation industries, through both direct sales and supply and
distribution agreements with major agrichemical industry partners. Plant Health
Care's products create both environmental and economic benefits for our
customers and capitalise upon long-term trends towards natural systems and
biological products to provide plant health and growth.

A blue star shines brightly in a sea of red (referring to my portfolio) PHC is class ! The chart is self explanatory . It seems to be just me posting here ,but shall keep posting anyway.

Neil, I took my profits last year, could have more but hey I'm happy with the tripling my money on this. Take a look at PIM who are much smaller than PHC but also have environmentally friendly solutions to increasing crop yields and dealing with parasite issues. They are at similar stage to PHC 2 years ago and IMO there is a good chance sp will rise once strategic deals are in place.
I recently bought in at 46.95p and expecting good profit long-term. Expect some announcements over the coming months.

Thanks for that Andy ,I will take a good look at PIM, and good to hear you made an excellent return.
Neil

RNS Number : 8083V
Plant Health Care PLC
03 June 2008






3 June 2008


For immediate release







Plant Health Care plc

('Plant Health Care' or 'the Company')




FIELD TRIALS

Pre-Tect delivers strong results in UK fruit trials







Plant Health Care plc (AIM: PHC.L), a leading provider of natural products for plants and soil, is pleased to report the success of independent UK trials of its Harpin based PreTect product on cherries, published in Horticulture Week, and on other soft fruit including strawberries and raspberries.




The trials undertaken by Farm Advisory Services Team ('FAST') have shown that protein-based Pre-Tect can help cherries from cracking during wet harvests and help to increase the shelf-life of soft fruits.




The results of the trials demonstrated that cherries from an orchard where an alternative material was applied with calcium and which experienced 110mm of rainfall exhibited 55 per cent cracking on the day sampled. Following more rainfall, the orchard was written off. In contrast, cherries from an orchard treated with PreTect and calcium, which were exposed to the same amount of rain, exhibited only 2.5 per cent cracking when sampled at the same time.




'Where no anti-crack treatment measures were taken the crop was a total write-off. Where alternative materials were used, some reduction in cracking was initially seen, but with continuing wet weather most fruits succumbed and growers walked away from the crop. However, where a full programme of PreTect was used, virtually no cracking was seen - even with over 120mm of rain falling during the main picking period' - said Don Vaughan, FAST's cherry agronomist. The trials were undertaken last summer when more than 200mm of rain fell during the cherry harvesting period'.




One of the growers participating in the trial, Henry Bryant of Faversham based Bryant & Partners, used Pre-Tect on his cherries in 2007 and also experienced good results. He said 'Without Pre-Tect I doubt we would have picked even 10 per cent of our cherries last year. As it was, we picked at least 80 per cent of the crop. An added bonus was the extended shelf life Pre-Tect appeared to give the fruit. This was remarked on by several customers when they compared our fruit to others'.




Other trials on strawberry 'Elsanta', 'Everest' and 'Symphony' varieties involved an application of PreTect two weeks before harvest. Results showed that the control fruit exhibited 20% rot whilst test fruit showed only 8% rots. Both were stored at 20oc for 14 days.




The 'Octavia' variety was used for raspberry trials again treated two weeks before harvest. Control fruit showed 40% rots whilst fruit treated with PreTect showed 10% rots following storage at 10oc for 14 days.




An excessively wet picking season in 2007 resulted in traditional botrytis treatments being 'maxed out' early in the season. With the added benefit of no harvest interval, however, Pre-Tect could be used to the day of harvest, extending the fruit's storage capability by 20%. 'When aimed at extending the shelf life of soft fruit, PreTect has proved excitingly effective,' said Rob Cook, soft fruit agronomist with FAST.




Charles Atkins of C.E. Murch at Blean, Canterbury used PreTect on his raspberry crop for the first time in 2007. 'There was a definite increase in fruit firmness at harvest time and I believe this is having a positive effect on the shelf life of my crop. This has been remarked upon by my customers'.




-Ends-




For further information please visit www.planthealthcare.com or contact:

Plant Health Care says in talks with agri cos for Myconate, Harpin products
AFX


LONDON (Thomson Financial) - Plant Health Care PLC. said it is in talks with several agriculture companies regarding the use of its Myconate and Harpin technologies on additional crops.

The company also said it remains on track to announce another important Harpin deal with one of the world's leading agricultural companies in the near term.



TFN.newsdesk@thomson.com

RNS Number : 6942W
Plant Health Care PLC
13 June 2008

TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES




1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):




PLANT HEALTH CARE plc




2. Reason for the notification (please state Yes/No): ( )

An acquisition or disposal of voting rights: (YES)

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( )

An event changing the breakdown of voting rights: ( )

Other (please specify): ()




3. Full name of person(s) subject to the notification obligation (iii):




Generation Investment Management LLP




4. Full name of shareholder(s) (if different from 3.) (iv):




Generation IM Climate Solutions Fund, L.P.




5. Date of the transaction (and date on which the threshold is crossed or reached if different) (v):

10/06/2008

6. Date on which issuer notified:




12/06/2008




7. Threshold(s) that is/are crossed or reached:



5%




8. Notified details:




A: Voting rights attached to shares




Class/type of shares if possible using the ISIN CODE
Situation previous to the Triggering transaction (vi)



Number of shares
Number of voting Rights (viii)

GB00B01JC540
1,640,000
1,640,000





Resulting situation after the triggering transaction (vii)

Class/type of shares if possible using the ISIN CODE
Number of shares

Number of voting rights (ix)

% of voting rights






Direct (x)
Indirect (xi)
Direct
Indirect

GB00B01JC540
2,355,000


2,355,000


5.256%





B: Financial Instruments




Resulting situation after the triggering transaction (xii)




Type of financial instrument




Expiration Date (xiii)






Exercise/Conversion Period/Date (xiv)





Number of voting rights that may be acquired if the instrument is exercised/ converted.



% of voting rights



















Total (A+B)




Number of voting rights



% of voting rights

2,355,000
5.256%





9. Chain of controlled undertakings through which the voting rights and/or the financial instruments
are effectively held, if applicable (xv):




Generation Investment Management LLP - Indirect:

Generation IM Climate Solution Fund, L.P. : 2,355,000 5.256% = Total Position




Proxy Voting:




10. Name of the proxy holder:




N/A




11. Number of voting rights proxy holder will cease to hold:




N/A




12. Date on which proxy holder will cease to hold voting rights:




N/A




13. Additional information:




Notification is based on using the total voting rights figure of 44,802,000.




14. Contact name:




(i) Andrew Wood FCIS, Company Secretary




(II) Tim Redfern, Evolution Securities Limited




(iii) Jeremy Carey, Tavistock Communications




15. Contact telephone number:




+44 (0)20 8866 5702

+44 (0)20 7071 4300

+44 (0)20 7920 3150




Annex to Notification Of Major Interests In Shares (xvi)




A: Identity of the person or legal entity subject to the notification obligation




Full name (including legal form for legal entities):




Generation Investment Management LLP




Contact address (registered office for legal entities):




4 Cork Street
London
W1S 3LG




Phone number:




020 7534 4700




Other useful information (at least legal representative for legal persons):




Peter Harris




B: Identity of the notifier, if applicable (xvii)




Full name:







Contact address:





Phone number:




Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)




END

13 June 2008

4 July 2008










Plant Health Care plc

('Plant Health Care' or 'the Company')




More Potential Benefits Indicated for Plant Health Care's Myconate




VA Mycorrhizal fungi produce glomalin,

a soil constituent that locks up soil carbon




Plant Health Care (AIM: PHC.L), a leading provider of natural products for plants and soil announces that the United States Department of Agriculture, Agricultural Research Service (USDA-ARS) has found that a soil constituent known as glomalin and produced by beneficial vesicular arbuscular mycorrhizal fungi (VAM) locks up soil carbon. VAM development and colonisation of plant roots is known to be stimulated by Plant Health Care's Myconate. The findings on glomalin come from research conducted by Kristine Nichols, a microbiologist at the USDA-ARS in Mandan, North Dakota. The report is based in part on carbon-dating studies of glomalin.




Dr. Greg Lewis, Vice President, Corporate Development at Plant Health Care says: 'VAM fungi act as a secondary plant root system, increasing a crop's ability to access and use available moisture and nutrients. By taking advantage of these known benefits of VA mycorrhizal fungi, growers can now not only improve the performance of their crops and enhance soil fertility, they may also be able to contribute to the long-term reduction of carbon dioxide from the atmosphere. Our Myconate product has been shown to encourage the development of VAM fungi in a growing number of agricultural crops.'




Glomalin is a sticky substance secreted by threadlike fungal structures called hyphae that funnel nutrients and water to plant roots. It is named after the Glomerales, the group of fungi to which some VAM fungi belong. So far, VAM fungi appear to be the only producers of glomalin.




Greg Lewis added, 'Plant Health Care has known for some time the benefits of mycorrhizal fungi, including the Glomerales, to plants and the soil and it is most encouraging to see the ARS document that these same organisms can contribute to carbon storage in soils. The ARS suggests that glomalin can keep carbon from decomposing for up to100 years. This is significant for the reduction of carbon dioxide in the atmosphere.'




Plant Health Care offers the product Myconate, which stimulates the colonization of plants by native VAM fungi already present in the soil. Myconate offers the potential to increase yields and tests are underway to determine if the expanded root mass observed on Myconate-treated crops will allow for a reduction in irrigation and nutritional inputs as well. Preliminary on-farm trials have shown very promising results in row crops, cereals and several vegetable crops such as carrots, potatoes and celery. Other potential crops being studied include perennials like fruits and vines and more vegetable crops like peppers, tomatoes and cucurbits. Myconate can be applied to a seed or watered into the ground very easily via irrigation systems. Myconate's net effect is to stimulate the colonization of native VAM soil fungi on plant roots, improving a crop's ability to access moisture and nutrients.




- Ends -




For Further Information:




John Brady
Evolution Securities Limited
Tavistock Communications

Chief Executive
Tim Worlledge/Grant Schaffer
Jeremy Carey/Simon Compton

Tel: 001 603 525 3702
Tel: 020 7071 4300
Tel: 020 7920 3150








Myconate, ProAct, N-Hibit PHC, and the Plant Health Care, Inc. logo are trademarks of Plant Health Care, Inc.




Notes to editors:

'Glomalin is Key to Locking up Soil Carbon' By Don Comis was published on June 17, 2008 on the USDA-ARS website at www.ars.usda.gov/is/pr/2008/080617.htm?pf=1







About Plant Health Care




Plant Health Care plc is a leading provider of natural products for plants and soil. Established in 1995 in Pittsburgh (Pennsylvania) in the United States, PHC currently has approximately 70 employees and has operations in the United States, Mexico, the United Kingdom, Spain, and the Netherlands. The Company listed on the AIM market of the London Stock Exchange in July 2004. Ticker symbol is PHC.




PHC's products are aimed at the landscape, agriculture and land reclamation industries and are environmentally beneficial. Through the commercialization of these products, PHC is capitalizing on current long-term trends toward natural systems and biological products for plant care and soil and water management. Further information is available at: www.planthealthcare.com.





This information is provided by RNS
The company news service from the London Stock Exchange

You cant keep a good share down!

RNS Number : 0328E
Plant Health Care PLC
23 September 2008






23 September 2008










Plant Health Care plc

('Plant Health Care' or 'the Company')







IMPRESSIVE YIELD GAINS FROM PRETECT TRIALS




Plant Health Care (AIM: PHC.L), a leading provider of natural products to the agriculture and landscape industries, announces that independent trials of PreTect, the Harpin based foliar fertiliser, have resulted in impressive yield gains across a variety of crops.




The trials were undertaken in Spain, by SICOP a Spanish government approved trials agency, over the past 12 months as part of government required efficacy tests. The results of tests on olives, tomatoes, strawberries and lettuce showed significant improvements across a number of key metrics. These trial results were the final requirement for full registration of Harpin across all crops in Spain and will enable PHC to make shelf life and vigor claims in that market.




When a small amount of PreTect was applied to tomatoes, it led to an increase in flowering and fruiting maturity, and an increase of 2.6% in yield and over 20% in the key category of firmness. The increase in firmness is the parameter that dictates the shelf-life of tomatoes and therefore helps reduce wastage and increase farmers' profits. There were over 3.6 million tonnes of tomatoes produced in Spain in 2007.




Tests on olives showed an increase of 3.3% in yield and 5.4% in fruit size and most importantly a significant increase in oil content. There are currently around six million acres of olives harvested in Spain per year.




Results on lettuce indicated increases in yield of 4.3% per lettuce head and strawberries showed average increases of 5.8%.




John Brady, CEO of Plant Health Care commented, 'These results further validate the efficacy of PreTect following the announcement in June 2008 of its successful trials across a variety of soft fruits.




'A wealth of data has shown that PreTect offers an effective method of increasing the yield and shelf-life of a variety of crops. These results help to further position Plant Health Care as a key player in the worldwide effort to increase food production and quality while also reducing synthetic chemical use.'




- ends -




For Further Information:




John Brady
Evolution Securities Limited
Tavistock Communications

Chief Executive
Tim Worlledge/Tim Redfern
Jeremy Carey/Simon Compton

Tel: 001 603 525 3702
Tel: 020 7071 4300
Tel: 020 7920 3150